BioSpace News Archive

Intellipharmaceutics International Inc. a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three months ended February 28, 2021.

Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO (gNO) for the treatment of solid tumors, today announced that Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, is scheduled to participate in two upcoming virtual investor conferences in May 2021.

Aruna Bio, Inc., a leader in the development of neural exosomes for the treatment of neurodegenerative diseases, today announced the closing of a common stock financing totaling $10.8 million.

Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced a new global partnership with Aidoc, the leading provider of enterprise artificial intelligence (“AI”) solutions, to accelerate the adoption and the clinical impact of AI to advance the timely detection and treatment of pulmonary embolism (“PE”).

- Papilocare® demonstrates efficacy of in healing cervical lesions 6 months after treatment in 88% of patients affected by high-risk HPV - Papilocare® cleared HPV lesions in 63% of patients with high-risk HPV compared with 40% in the control group - BioVaxys has right of refusal for US marketing of Papilocare®

- Provides easier access to genetic testing for patients with symptoms or diagnosis of cerebral palsy at no charge -

A compact, ergonomic benchtop unit designed to fit in almost any laboratory or production line setup, the LT-Pro Leak Tester is suitable for pharmaceutical, food and beverage, and personal care applications.

Spectrum Solutions , LLC today announced David J. Vigerust, MS., PhD. has been named the company’s new Chief Scientific Officer. Dr. Vigerust has founded, led as CEO, and previously served as chief scientific officer for a number of progressive life science and advanced biotech companies.

- Marketing Authorization Application (MAA) Submission in Europe Planned for Q4 2021 - Phase 3 Trial in Europe and U.S. Expected to Begin in Q3 2021 to Support Regulatory Submissions

Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that since the Company began offering SARS-CoV-2 testing services in June 2020, it has now received more than 350,000 samples for testing.